Trial NCT01712217, which explores crizotinib in combination with HSP90 inhibitor AT13387, is recruiting patients with both ALK- and ROS1-positive NSCLC who have failed crizotinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.